Analytical Data
-
基因名
CRADD
- Application
-
别名
Caspase and RIP adapter with death domain RIP-associated protein with a death domain
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P78560
-
表达区间
1-199aa
-
分子量
38.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CRADD (Caspase-8-Activating Adaptor Protein) is a key player in the apoptotic signaling pathways, particularly in mediating the interaction between death receptors and caspases, which are crucial for inducing programmed cell death. Its role has been linked to various cellular processes such as cell differentiation, proliferation, and survival, making it a focal point of interest in cancer research and therapeutic developments. The study of CRADD's structure and its functional domains has garnered attention for potential implications in understanding how dysregulation of apoptosis contributes to tumorigenesis and resistance to chemotherapy. Additionally, the ability of CRADD to interact with other apoptotic proteins suggests that it may serve as a strategic target for novel cancer treatments that aim to restore the apoptotic pathways impaired in cancer cells. By utilizing recombinant DNA technology, researchers are exploring the production of CRADD fusion proteins to investigate their biological activity, interactions, and potential therapeutic applications. Ultimately, these studies aim to develop strategies that harness CRADD's apoptotic capabilities to enhance cancer treatments and improve patient outcomes. Through in-depth characterization of CRADD and its role in apoptotic signaling, researchers strive to provide valuable insights that could lead to innovative approaches in combating various forms of cancer.
